Passage BIO, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Passage BIO, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2019 to Q3 2024.
  • Passage BIO, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $1.4M, a 50.4% decline year-over-year.
  • Passage BIO, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $6.14M, a 52.1% decline year-over-year.
  • Passage BIO, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $10.9M, a 42.4% decline from 2022.
  • Passage BIO, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $19M, a 42% decline from 2021.
  • Passage BIO, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $32.7M, a 124% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $6.14M $1.4M -$1.42M -50.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $7.57M $1.58M -$2.17M -57.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $9.73M $1.6M -$1.19M -42.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $10.9M $1.57M -$1.91M -54.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-04
Q3 2023 $12.8M $2.82M -$38K -1.33% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $12.9M $3.74M -$2.54M -40.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $15.4M $2.78M -$3.55M -56.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $19M $3.48M -$4.1M -54.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-04
Q3 2022 $23.1M $2.86M -$3.95M -58% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $27M $6.28M -$2.28M -26.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $29.3M $6.34M -$3.4M -34.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $32.7M $7.58M +$3.25M +75.2% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-06
Q3 2021 $29.4M $6.82M +$2.78M +69% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $26.7M $8.56M +$4.71M +122% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $22M $9.74M +$7.37M +311% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $14.6M $4.32M +$3.29M +317% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-03
Q3 2020 $11.3M $4.03M +$3.94M +4145% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $7.35M $3.86M +$3.76M +4090% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $3.59M $2.37M +$2.14M +925% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $1.45M $1.04M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-03
Q3 2019 $95K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 $92K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 $231K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.